MIMS: Latest findings on hormonal contraceptives

The MHRA has published drug safety advice including the latest evidence on hormonal contraceptives.

One of the topics discussed is the further evidence to suggest that the long-term use of combined oral contraceptives (COCs) or progestogen-only injectable contraceptives is associated with a small increased risk of cervical cancer.

These findings have come from a report which re-analysed data from more than 16,500 women with cervical cancer and found that current use of COCs for five years or longer is accompanied by an increased risk of cervical cancer (relative risk 1.90 [95% CI 1.69–2.13]).

The MHRA has produced a question-and-answer sheet and information sheet for women about cervical cancer and hormonal contraceptives.

In another topic, the MHRA discuss study data on the risk of venous thromboembolism (VTE) in two combined contraceptives, Yasmin (30 micrograms ethinylestradiol/3mg drospirenone) and Evra (20 micrograms ethinylestradiol/150 micrograms norelgestromin).

The results suggest that the risk of venous thromboembolism in users of Yasmin is in the same range as that for users of COCs that have low ethinylestradiol dose, including second-generation pills.

The risk in users of the Evra contraceptive patch may be slightly increased compared with that for users of second-generation pills.

Further information: MHRA website


Have you registered with us yet?

Register now to enjoy more articles and free email bulletins


Already registered?

Sign in